MedPath

The Incidence and Risk Factors of Neonatal Hyperbilirubinemia in Term and Late-preterm Chinese Infants

Completed
Conditions
Hyperbilirubinemia, Neonatal
Registration Number
NCT01762189
Lead Sponsor
Nanjing Medical University
Brief Summary

Thirteen hospitals in China will participate in the study, which aims to provide data on serum bilirubin levels in the first 168 hr after birth in term and late-preterm neonates, and estimate the incidence of severe neonatal hyperbilirubinemia and the underlying causes.

We hypothesize that the study can be value in identifying and implementing strategies for risk reduction.

Detailed Description

Neonatal hyperbilirubinemia resulting in clinical jaundice is a common problem among infants, particularly during the first weeks of life.

Information about the incidence and risk factors of neonatal jaundice is not available from China where is one of the highest countries of the incidence of severe neonatal hyperbilirubinemia.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
13157
Inclusion Criteria

Term or late-preterm newborn infants with GAs of β‰₯35 weeks and birth weights of β‰₯2,000 g were included.

Exclusion Criteria

All sick newborn infants who were admitted to the intensive care unit.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The incidence of severe neonatal hyperbilirubinemiaAt the 28 days after birth

Significant hyperbilirubinemia was defined as any TSB level that exceeded the hour-specific threshold value for phototherapy, according to the guidelines presented by the American Academy of Pediatrics.

Secondary Outcome Measures
NameTimeMethod
Number of participants with risk factors associated with severe neonatal hyperbilirubinemiaAt the 28 days after birth

The risk factors recognized to be associated with significant hyperbilirubinemia in newborns have included gestational age, weight for Gestational Age, delivery mode, gender, previous infant had phototherapy, bruising/cephalahematoma, feeding mode, excessive body weight loss, and early discharge, et al.

Trial Locations

Locations (14)

Nanjing Maternity and Child Health Care Hospital of Nanjing Medical University

πŸ‡¨πŸ‡³

Nanjing, Jiangsu, China

Children's Hospital of Fudan University

πŸ‡¨πŸ‡³

Shanghai, China

Guangdong Maternal and Children's Hospital, Guangzhou Medical College

πŸ‡¨πŸ‡³

Guangzhou, Guangdong, China

Guangxi Maternal and Child Health Hospital

πŸ‡¨πŸ‡³

Liuzhou, Guangxi, China

Guiyang Maternal and Child Health Hospital

πŸ‡¨πŸ‡³

Guiyang, Guizhou, China

The First Hospital of Harbin Medical University

πŸ‡¨πŸ‡³

Harbin, Heilongjiang, China

The First Affiliated Hospital of Zhengzhou University

πŸ‡¨πŸ‡³

Zhengzhou, Henan, China

Inner Mongolia Maternal and Child Health Care Hospital

πŸ‡¨πŸ‡³

Hohhot Shi, Inner Mongolia, China

Jinlin Provincial Maternal and Child Health Hospital

πŸ‡¨πŸ‡³

Changchun, Jilin, China

Shaanxi Provincial Maternal and Child Health Hospital

πŸ‡¨πŸ‡³

Taiyuan, Shaanxi, China

Sichuan Provincial People's Hospital

πŸ‡¨πŸ‡³

Chengdu, Sichuan, China

The First Hospital of Xinjiang Medical University

πŸ‡¨πŸ‡³

Ürümqi, Xinjiang, China

Gynecology and Obstetrics Hospital, Fudan University

πŸ‡¨πŸ‡³

Shanghai, China

The Third Hospital of Peking University

πŸ‡¨πŸ‡³

Beijing, China

Β© Copyright 2025. All Rights Reserved by MedPath